Posts Tagged ‘CollabRx’

CollabRx Launches Commercial Service for the Interpretation of Clinical Cancer Sequencing

SAN FRANCISCO, Aug. 8, 2013 (GLOBE NEWSWIRE) — CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, today announced the launch of the company’s Genetic Variant Annotation™ (GVA™) service. The GVA service is a new product and the company’s first offering for the clinical laboratory market. CollabRx will provide the GVA service to the molecular diagnostic segment of the clinical laboratory market which includes reference laboratories, hospital laboratories, research institutions, and laboratories within academic medical centers. Read more

CollabRx and OncoDNA Partner in Molecular Diagnostics

CollabRx, Inc, a data analytics company focused on informing clinical decision making in molecular medicine, and OncoDNA, SA, a Belgium company that provides DNA next generation sequencing (NGS) tests for clinical use in cancer, today announced a multi-year agreement to purchase CollabRx SaaS-based technology and content resources to be used in conjunction with OncoDNA’s cancer mutation panels. Read more

CollabRX Creates Editorial Board for Prostate Cancer

Following the news earlier this month that CollabRX has released a semantic clinical support tool for oncologists, CollabRX has formed a new editorial board for prostate cancer. According to the article, “CollabRx, Inc. [yesterday] announced the formation of an editorial board for prostate cancer to be led by E. David Crawford, M.D. who will serve as Chief Editor. Dr. Crawford is the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. He is an active clinician, researcher, and teacher who has been recognized as one of the Best Doctors in America, one of the Best Cancer Doctors, and one of the Top 20 Urologists in the country by Men’s Health Magazine. Dr. Crawford will lead a distinguished group of physicians from leading institutions such as Yale University, University of Michigan, Cleveland Clinic, Dana-Farber Cancer Institute, and others.” Read more

CollabRx Releases Semantic Clinical Support Tool for Oncologists

According to a new article out of the company, “CollabRx, Inc. today announced the release of a new version of its Therapy Finder™ application (‘app’) for lung cancer. The lung cancer Therapy Finder™app is a web-based decision support tool that enables oncologists to take into account the genetics of a patient’s tumor when determining a treatment plan. The newest lung cancer Therapy Finder™ is currently freely available at the company’s website and via distribution partners such as MedPage Today, Everyday Health’s physician portal (http://www.medpagetoday.com/resource-center/lung-cancer-therapy/therapy-finder).” Read more